We are a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets.
|Oct12||SteadyMed Receives Notice of Allowance for its European Patent Relating to Enhanced Reduction of Infusion-Site Pain|
|Sep28||SteadyMed Submits Type A Meeting Request Package to FDA|
|Aug31||SteadyMed Receives Refusal to File Letter from FDA for Trevyent® New Drug Application|
SteadyMed and the Pulmonary Hypertension Association (PHA) California Chapter launched the PHenomenal campaign, asking people with pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH), along with their loved ones, to submit photos and videos showing how they refuse to let the disease define their lives. Submissions should be tagged with #PHenomSelf on Tumblr, Instagram, Facebook and Twitter. People can also learn more about the campaign and see others’ submissions on our Tumblr (www.tumblr.com/blog/phenomself) and Instagram (www.instagram.com/phenomself") pages. Together let’s celebrate the unique and inspiring faces behind PAH and PH!